Navigation Links
BioSpecifics Technologies Corp. to Present at the Aegis Capital 2013 Healthcare Conference
Date:9/19/2013

LYNBROOK, N.Y., Sept. 19, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products marketed as XIAFLEX® in the U.S and XIAPEX® in the EU, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the Aegis Capital 2013 Healthcare Conference.

The presentation will take place on Thursday, September 26, 2013 at 4:00 p.m. EDT (1:00 p.m. PDT) at the Encore at Wynn hotel in Las Vegas, NV. This event will not be webcast.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is currently marketed as XIAFLEX® (collagenase clostridium histolyticum (CCH)) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium) and marketed in Europe and approved in Canada. Swedish Orphan Biovitrum AB has marketing rights for XIAPEX® (the EU tradename for CCH) for the treatment of Dupuytren's contracture and Peyronie's disease in 71 Eurasian and African countries. Asahi Kasei Pharma Corporation has development and commercialization rights for XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease in Japan and Actelion Pharmaceuticals Ltd. has development and commercialization rights for XIAFLEX for these two indications in Canada, Mexico, Brazil and Australia. CCH is in clinical development for the treatment of several additional promising indications. The PDUFA date for XIAFLEX for Peyronie's disease is December 6, 2013. Auxilium is also testing CCH for frozen shoulder syndrome and cellulite. Auxilium expects to initiate a Phase II trial of CCH for cellulite in the third quarter of this year and next stage trials of CCH for frozen shoulder syndrome in the fourth quarter of 2013. BioSpecifics is currently managing the development of CCH for the treatment of human and canine lipomas, both of which are in Phase II trials. BioSpecifics expects top-line data from these trials in the second half of the year. For more information, please visit www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. to Present at the Stifel Nicolaus 2013 Healthcare Conference
2. BioSpecifics Technologies Corp. Reports Second Quarter 2013 Financial Results
3. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2013 Financial Results on Thursday, August 8, 2013
4. BioSpecifics Technologies Corp. to Present at Jefferies 2013 Global Healthcare Conference
5. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013
6. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
7. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
8. BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
9. BioSpecifics Technologies Corp. to Webcast, Live, at RetailInvestorConferences.com on December 6th
10. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
11. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/10/2016)... February 10, 2016 Demonstrates ... 1 receptor selectivity   1 ... which has entered clinical development as a new ... and schizophrenia.   --> 1 ... has entered clinical development as a new treatment ...
(Date:2/9/2016)... 9, 2016  Insulet Corporation (NASDAQ: PODD ) (Insulet ... technology with its OmniPod ® Insulin ... has been appointed to Insulet,s Board of Directors. With his ... of whom are independent. --> ... and finance experience and a deep knowledge of accounting, financial ...
Breaking Medicine Technology:
(Date:2/10/2016)... La Puente, California (PRWEB) , ... February 09, ... ... Dental Medicine students, faculty and staff helped give free oral screenings to 150 ... California Feb. 5, 2016. , The College of Dental Medicine joined Chinese American ...
(Date:2/9/2016)... Fort Lauderdale, Florida (PRWEB) , ... February 09, 2016 , ... ... known as the Taste of South Florida Event, an upscale fundraiser held in South ... to wow sponsors and guests alike. This year the event will be held in ...
(Date:2/9/2016)... ... February 09, 2016 , ... A new study ... rates and Medicare rates for a variety of medical services in Illinois as ... of the 2015 Fee Schedule Rates in Illinois, are professional medical services, ...
(Date:2/9/2016)... ... , ... On January 12, 2016 Paul McElwee, a CroppMetcalfe HVAC technician, visited ... not producing any heat. Shortly after entering the home, Paul was able to identify ... levels of carbon monoxide into the home, at 2,000 parts per million in the ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... The guide will ensure lab personnel have a basic understanding of the techniques ... measurement protocols. Enhanced understanding will help them reduce waste and rework to create ...
Breaking Medicine News(10 mins):